Taconic Capital Advisors’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Taconic Capital Advisors’s Portfolio NKGN Stock Details NKGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-350,000	Closed	-$3.48M	–	334
2022 Q4	$3.48M	Hold	350,000	–	–	0.1%	201
2022 Q3	$3.41M	Hold	350,000	–	–	0.08%	254
2022 Q2	$3.4M	Hold	350,000	–	–	0.09%	257
2022 Q1	$3.4M	Hold	350,000	–	–	0.09%	253
2021 Q4	$3.39M	Hold	350,000	–	–	0.1%	215
2021 Q3	$3.39M	Buy	+350,000	New	+$3.41M	0.09%	169

Other funds holding NKGN

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return

CIM

Cowen Investment Management New York $12M AUM 1.47% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

SIM

Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return

RCM

Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return

Taconic Capital Advisors's NKGN Position: Q1 2023 in Review

Taconic Capital Advisors sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q1 2023, closing a stake of 350,000 shares — an estimated $3.48M sold.

Taconic Capital Advisors first reported a position in NKGN in Q3 2021 and held it in 6 quarters. The position peaked at $3.48M in Q4 2022. 55 funds tracked by Wall St. Rank hold NKGN as of Q1 2023.

Taconic Capital Advisors reported no remaining NKGen Biotech, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Taconic Capital Advisors sold 350,000 NKGen Biotech, Inc. Common Stock shares in Q1 2023, an estimated $3.48M.
Taconic Capital Advisors first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2021 and held it in 6 quarters.
Taconic Capital Advisors's NKGen Biotech, Inc. Common Stock position peaked at $3.48M in Q4 2022.
55 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q1 2023.

Based on Taconic Capital Advisors's 13F filing for Q1 2023, filed 15 May 2023.